Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP4K4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP4K4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP4K4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP4K4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP4K4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAP4K4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP4K4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:0150115110 | Esophagus | ESCC | cell-substrate junction organization | 77/8552 | 101/18723 | 3.46e-10 | 9.57e-09 | 77 |
GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
GO:004804116 | Esophagus | ESCC | focal adhesion assembly | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:001081126 | Esophagus | ESCC | positive regulation of cell-substrate adhesion | 84/8552 | 123/18723 | 3.18e-07 | 4.50e-06 | 84 |
GO:005140318 | Esophagus | ESCC | stress-activated MAPK cascade | 147/8552 | 239/18723 | 5.43e-07 | 7.18e-06 | 147 |
GO:000195217 | Esophagus | ESCC | regulation of cell-matrix adhesion | 85/8552 | 128/18723 | 1.70e-06 | 2.02e-05 | 85 |
GO:000716018 | Esophagus | ESCC | cell-matrix adhesion | 141/8552 | 233/18723 | 3.33e-06 | 3.71e-05 | 141 |
GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
GO:015011619 | Esophagus | ESCC | regulation of cell-substrate junction organization | 51/8552 | 71/18723 | 6.99e-06 | 7.04e-05 | 51 |
GO:007030217 | Esophagus | ESCC | regulation of stress-activated protein kinase signaling cascade | 119/8552 | 195/18723 | 1.07e-05 | 1.01e-04 | 119 |
GO:005189318 | Esophagus | ESCC | regulation of focal adhesion assembly | 47/8552 | 66/18723 | 2.31e-05 | 1.98e-04 | 47 |
GO:009010918 | Esophagus | ESCC | regulation of cell-substrate junction assembly | 47/8552 | 66/18723 | 2.31e-05 | 1.98e-04 | 47 |
GO:003287217 | Esophagus | ESCC | regulation of stress-activated MAPK cascade | 116/8552 | 192/18723 | 2.63e-05 | 2.21e-04 | 116 |
GO:00072549 | Esophagus | ESCC | JNK cascade | 102/8552 | 167/18723 | 4.22e-05 | 3.39e-04 | 102 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4K4 | SNV | Missense_Mutation | | c.3526N>T | p.Val1176Phe | p.V1176F | | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.98) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.3715N>C | p.Phe1239Leu | p.F1239L | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP4K4 | SNV | Missense_Mutation | | c.451N>T | p.His151Tyr | p.H151Y | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.643N>A | p.Asp215Asn | p.D215N | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.1246G>C | p.Glu416Gln | p.E416Q | | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.888) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.592N>A | p.Glu198Lys | p.E198K | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.673N>C | p.Glu225Gln | p.E225Q | | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.2322N>C | p.Leu774Phe | p.L774F | | protein_coding | tolerated_low_confidence(0.59) | probably_damaging(0.991) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.2741N>C | p.Gly914Ala | p.G914A | | protein_coding | tolerated_low_confidence(0.39) | probably_damaging(0.997) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP4K4 | insertion | Nonsense_Mutation | novel | c.1598_1599insGGAGGGTCAGACATAGACACAAGAGACGTAGAT | p.Asp533delinsGluGluGlyGlnThrTerThrGlnGluThrTerIle | p.D533delinsEEGQT*TQET*I | | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CEP-1347 | CEP-1347 | 24044867 |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | GW843682X | GW843682X | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PF-562271 | PF-00562271 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | R-1487 | R-1487 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565814 | | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CENISERTIB | CENISERTIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | anastrozole | ANASTROZOLE | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SP-600125 | SP-600125 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | ENTRECTINIB | ENTRECTINIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SB-203580 | SB-203580 | |